Die wichtigsten Phase-III-Studien im Überblick

<p class="article-content"><table border="1" width="100 % " cellspacing="0" cellpadding="0"><colgroup><col width="10 % " /> <col width="17 % " /> <col width="60 % " /> <col width="13 % " /> </colgroup> <tbody> <tr> <td class="xl65" style="padding: 5px; text-align: center;" width="90" height="25"> <h4>Abstr. #</h4> </td> <td class="xl65" style="padding: 5px; text-align: center;" width="150"> <h4>Erstautor</h4> </td> <td class="xl65" style="padding: 5px;" width="959"> <h4>Titel</h4> </td> <td class="xl65" style="padding: 5px; text-align: center;" width="80"><strong>URL</strong></td> </tr> <tr> <td class="xl66" style="padding: 5px;" colspan="4" height="20"> <h4>Chronische Lymphatische Leuk&auml;mie</h4> </td> </tr> <tr> <td style="text-align: center;" height="20">S105</td> <td style="padding: 5px; text-align: center;">Stilgenbauer S</td> <td style="padding: 5px;">Genetic markers and outcome in the CLL14 trial of the GCLLSG comparing front line obinutuzumab plus chlorambucil or venetoclax in patients with comorbidity</td> <td class="xl68" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267306/stephan.stilgenbauer.genetic.markers.and.outcome.in.the.cll14.trial.of.the.html?f=menu%3D14%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Aspeaker % 3D34907" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S106</td> <td style="padding: 5px; text-align: center;">Al-Sawaf O</td> <td style="padding: 5px;">High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype (CKT) and chronic lymphocytic leukemia (CLL): A prospective analysis from the CLL14 trial</td> <td class="xl68" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267307/othman.al-sawaf.high.efficacy.of.venetoclax.plus.obinutuzumab.in.patients.with.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DHigh+efficacy+of+venetoclax+plus+obinutuzumab+in+patients+with+complex+karyotype+%28CKT%29+and+chronic+lymphocytic+leukemia+%28CLL%29 % 3A+A+prospective+analysis+from+the+CLL14+trial" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S107</td> <td style="padding: 5px; text-align: center;">Tedeschi A</td> <td style="padding: 5px;">Five-year follow-up of patients receiving ibrutinib for first-line treatment of chronic lymphocytic leukemia</td> <td class="xl68" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267308/alessandra.tedeschi.five-year.follow-up.of.patients.receiving.ibrutinib.for.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3DFive-year+follow-up+of+patients+receiving+ibrutinib+for+first-line+treatment+of+chronic+lymphocytic+leukemia" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S109</td> <td style="padding: 5px; text-align: center;">Siddiqi T</td> <td style="padding: 5px;">TRANSCEND CLL 004: Minimal residual disease negative responses after lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma</td> <td class="xl68" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267310/tanya.siddiqi.transcend.cll.004.minimal.residual.disease.negative.responses.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Ds109" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS1123</td> <td style="padding: 5px; text-align: center;">Wu J</td> <td style="padding: 5px;">Impact of major genomic alterations on outcome of relapsed/refractory chronic lymphocytic leukemia patients treated with venetoclax plus rituximab in the phase 3 MURANO study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266740/jenny.wu.impact.of.major.genomic.alterations.on.outcome.of.relapsed.refractory.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DImpact+of+major+genomic+alterations+on+outcome+of+relapsed % 2Frefractory+chronic+lymphocytic+leukemia+patients+treated+with+venetoclax+plus+rituximab+in+the+phase+3+MURANO+study" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS1161</td> <td style="padding: 5px; text-align: center;">Greil R</td> <td style="padding: 5px;">Efficacy and safety of ibrutinib in relapsed/refractory chronic lymphocytic leukemia patients previously treated with venetoclax in the MURANO study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266778/richard.greil.efficacy.and.safety.of.ibrutinib.in.relapsed.refractory.chronic.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DEfficacy+and+safety+of+ibrutinib+in+relapsed % 2Frefractory+chronic+lymphocytic+leukemia+patients+previously+treated+with+venetoclax+in+the+MURANO+study" target="_blank">weiterlesen</a></td> </tr> <tr> <td class="xl66" style="padding: 5px;" colspan="4" height="20"> <h4>Chronische Myeloische Leuk&auml;mie</h4> </td> </tr> <tr> <td style="text-align: center;" height="20">S882</td> <td style="padding: 5px; text-align: center;">Malagola M</td> <td style="padding: 5px;">Optimization of TKI treatment in elderly patients with PH+ chronic myeloid leukemia and stable MR3.0 or MR4.0: 1st year results of the italian mulitcentric phase-III randomized OPTKIMA study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267465/michele.malagola.optimization.of.tki.treatment.in.elderly.patients.with.ph2B.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Ds882" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF413</td> <td style="padding: 5px; text-align: center;">Br&uuml;mmendorf TH</td> <td style="padding: 5px;">Cardiac, vascular, and hypertension safety of bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266213/tim.h.brmmendorf.cardiac.vascular.and.hypertension.safety.of.bosutinib.vs.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DCardiac%2C+vascular % 2C+and+hypertension+safety+of+bosutinib+vs+imatinib+for+newly+diagnosed+chronic+myeloid+leukemia+in+the+BFORE+trial" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS1195</td> <td style="padding: 5px; text-align: center;">Br&uuml;mmendorf TH</td> <td style="padding: 5px;">Time to health-related quality of life improvement in phase 3 BFORE trial: First-line bosutinib vs imatinib in chronic phase chronic myeloid leukemia</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266812/tim.h.brmmendorf.time.to.health-related.quality.of.life.improvement.in.the.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dps1195" target="_blank">weiterlesen</a></td> </tr> <tr> <td class="xl66" style="padding: 5px;" colspan="4" height="20"> <h4>Akute Lymphatische Leuk&auml;mie</h4> </td> </tr> <tr> <td style="text-align: center;" height="20">PS937</td> <td style="padding: 5px; text-align: center;">Rijneveld A</td> <td style="padding: 5px;">Randomized phase III HOVON-100 study of clofarabine combined with standard treatment in adult patients with newly diagnosed ALL</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267238/aw.rijneveld.randomized.phase.iii.hovon-100.study.of.clofarabine.combined.with.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3DRandomized+phase+III+HOVON-100+study+of+clofarabine+combined+with+standard+treatment+in+adult+patients+with+newly+diagnosed+ALL" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS950</td> <td style="padding: 5px; text-align: center;">Jabbour E</td> <td style="padding: 5px;">Efficacy and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated in the INO-VATE trial: Outcomes by salvage-treatment phase</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267251/elias.jabbour.efficacy.and.safety.of.inotuzumab.ozogamicin.in.patients.with.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DEfficacy+and+safety+of+inotuzumab+ozogamicin+in+patients+with+relapsed%2Frefractory+B-cell+acute+lymphoblastic+leukemia+treated+in+the+INO-VATE+trial % 3A+Outcomes+by+salvage-treatment+phase" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS951</td> <td style="padding: 5px; text-align: center;">Marks DI</td> <td style="padding: 5px;">More or less? Impact of dose number on outcomes of patients with acute lymphoblastic leukemia treated with inotuzumab ozogamicin</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267252/david.i.marks.more.or.less.impact.of.dose.number.on.outcomes.of.patients.with.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DMore+or+less % 3F+Impact+of+dose+number+on+outcomes+of+patients+with+acute+lymphoblastic+leukemia+treated+with+inotuzumab+ozogamicin" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS954</td> <td style="padding: 5px; text-align: center;">Jabbour E</td> <td style="padding: 5px;">Time from randomization to first subsequent induction/salvage therapy in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase 3 INO-VATE trial</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267255/elias.jabbour.time.from.randomization.to.first.subsequent.induction.salvage.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DTime+from+randomization+to+first+subsequent+induction%2Fsalvage+therapy+in+patients+with+relapsed % 2Frefractory+acute+lymphoblastic+leukemia+treated+with+inotuzumab+ozogamicin+in+the+phase+3+INO-VATE+trial" target="_blank">weiterlesen</a></td> </tr> <tr> <td class="xl66" style="padding: 5px;" colspan="4" height="20"> <h4>Akute Myeloische Leuk&auml;mie</h4> </td> </tr> <tr> <td style="text-align: center;" height="20">S876</td> <td style="padding: 5px; text-align: center;">Perl A</td> <td style="padding: 5px;">Gilterinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia (AML): Results from the phase 3 admiral trial</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267459/alexander.perl.gilteritinib.significantly.prolongs.overall.survival.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Ds876" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S879</td> <td style="padding: 5px; text-align: center;">Fenaux P</td> <td style="padding: 5px;">Results of ASTRAL-1 study, a phase 3 randomized trial of guadecitabine vs treatment choice in treatment naive acute myeloid leukemia (TN-AML) not eligible for intensive chemotherapy</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267462/pierre.fenaux.results.of.astral-1.study.a.phase.3.randomized.trial.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Ds879" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF251</td> <td style="padding: 5px; text-align: center;">Levis M</td> <td style="padding: 5px;">Gilterinib prolongs survival in patients with FLT3-mutated relapsed/refractory AML who have common AML co-mutations or a high FLT3-ITD allelic ratio</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266051/mark.levis.gilteritinib.prolongs.survival.in.patients.with.flt3-mutated.html" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF260</td> <td style="padding: 5px; text-align: center;">D&ouml;hner K</td> <td style="padding: 5px;">Prognostic and predictive impact of NMP1/FLT3-ITD genotypes as defined by 2017 European leukemia-net risk categorization from AML patients treated within the international RATIFY study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266060/konstanze.dhner.prognostic.and.predictive.impact.of.npm1.flt3-itd.genotypes.as.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dpf260" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF264</td> <td style="padding: 5px; text-align: center;">Russell N</td> <td style="padding: 5px;">Treatment intensification with flag-ida may improve disease control in younger patients with longer follow-up: Long-term analysis of the MRC AML15 trial</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266064/nigel.russell.treatment.intensification.with.flag-ida.may.improve.disease.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dpf264" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF293</td> <td style="padding: 5px; text-align: center;">Faderl S</td> <td style="padding: 5px;">Phase 3 exploratory analysis of outcomes in older adults with newly diagnosed, high-risk/secondary AML who achieved remission with CPX-351 versus 7+3 induction</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266093/stefan.faderl.phase.3.exploratory.analysis.of.outcomes.in.older.adults.with.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DPhase+3+exploratory+analysis+of+outcomes+in+older+adults+with+newly+diagnosed%2C+high-risk%2Fsecondary+AML+who+achieved+remission+with+CPX-351+versus+7 % 2B3+induction" target="_blank">weiterlesen</a></td> </tr> <tr> <td class="xl66" style="padding: 5px;" colspan="4" height="20"> <h4>Indolente Lympome</h4> </td> </tr> <tr> <td style="text-align: center;" height="20">S101</td> <td style="padding: 5px; text-align: center;">Rule S</td> <td style="padding: 5px;">Efficacy and safety of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results of the phase III MABCUTE study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267302/simon.rule.efficacy.and.safety.of.prolonged.maintenance.with.subcutaneous.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DEfficacy+and+safety+of+prolonged+maintenance+with+subcutaneous+rituximab+in+patients+with+relapsed+or+refractory+indolent+non-Hodgkin+lymphoma % 3A+Results+of+the+phase+III+MABCUTE+study" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF483</td> <td style="padding: 5px; text-align: center;">Leonard JP</td> <td style="padding: 5px;">Efficacy was improved with lenalidomide/rituximab (R2) vs rituximab/placebo in patients with follicular lymphoma irrespective of POD24 status in the phase III AUGMENT study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266283/john.leonard.efficacy.was.improved.with.lenalidomide.rituximab.28r229.vs.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DEfficacy+was+improved+with+lenalidomide%2Frituximab+%28R2%29+vs+rituximab % 2Fplacebo+in+patients+with+follicular+lymphoma+irrespective+of+POD24+status+in+the+phase+III+AUGMENT+study" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS1253</td> <td style="padding: 5px; text-align: center;">Rummel MJ</td> <td style="padding: 5px;">MAGNIFY: Phase IIIB interim analysis of induction R2 followed by maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266870/mathias.j.rummel.magnify.phase.iiib.interim.analysis.of.induction.r2.followed.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DMAGNIFY%3A+Phase+IIIB+interim+analysis+of+induction+R2+followed+by+maintenance+in+patients+with+relapsed % 2Frefractory+indolent+non-Hodgkin+lymphoma" target="_blank">weiterlesen</a></td> </tr> <tr> <td class="xl66" style="padding: 5px;" colspan="4" height="20"> <h4>Agressive Lymphome</h4> </td> </tr> <tr> <td style="text-align: center;" height="20">S1598</td> <td style="padding: 5px; text-align: center;">Trneny M</td> <td style="padding: 5px;">Baseline total metabolic tumor volume is highly prognostic for refractoriness to immunochemotherapy in DLBCL: An analysis of the phase 3 GOYA trial</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267352/marek.trneny.baseline.total.metabolic.tumor.volume.is.highly.prognostic.for.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DBaseline+total+metabolic+tumor+volume+is+highly+prognostic+for+refractoriness+to+immunochemotherapy+in+DLBCL % 3A+An+analysis+of+the+phase+3+GOYA+trial" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S1599</td> <td style="padding: 5px; text-align: center;">Lugtenburg P</td> <td style="padding: 5px;">Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-NORDIC lymphoma group phase III study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267353/pieternella.lugtenburg.rituximab.maintenance.for.patients.with.diffuse.large.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DRituximab+maintenance+for+patients+with+diffuse+large+B-cell+lymphoma+in+first+complete+remission % 3A+Results+from+a+randomized+HOVON-NORDIC+lymphoma+group+phase+III+study" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS1070</td> <td style="padding: 5px; text-align: center;">Illidge T</td> <td style="padding: 5px;">The ECHELON-2 trial: Results of a randomized, double-blind phase 3 study of brentuximab vedotin and CHP (A+CHP) vresus CHOP in frontline treatment of patients with CD30+ peripheral T-cell lymphomas</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266687/tim.illidge.the.echelon-2.trial.results.of.a.randomized.double-blind.phase.3.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dps1070" target="_blank">weiterlesen</a></td> </tr> <tr> <td class="xl66" style="padding: 5px;" colspan="4" height="20"> <h4>Multiples Myelom</h4> </td> </tr> <tr> <td style="text-align: center;" height="20">S145</td> <td style="padding: 5px; text-align: center;">Moreau P</td> <td style="padding: 5px;">Phase 3 randomized study of daratumumab + bortezomib/thalidomide/dexamethasone (D-VTd) versus VTd in transplant-eligible newly diagnosed multiple myeloma: Part 1 CASSIOPEIA results</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267346/philippe.moreau.phase.3.randomized.study.of.daratumumab.2B.bortezomib.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DPhase+3+randomized+study+of+daratumumab+%2B+bortezomib%2Fthalidomide%2Fdexamethasone+%28D-VTd%29+versus+VTd+in+transplant-eligible+newly+diagnosed+multiple+myeloma % 3A+Part+1+CASSIOPEIA+results" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S823</td> <td style="padding: 5px; text-align: center;">Mateos MV</td> <td style="padding: 5px;">Randomized, open-label, non-inferiority, phase 3 study of subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma: COLUMBA</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267406/mara-victoria.mateos.randomized.open-label.non-inferiority.phase.3.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Ds823" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S824</td> <td style="padding: 5px; text-align: center;">Attal M</td> <td style="padding: 5px;">A phase 3 randomized, open-label, multicenter study of isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267407/paul.richardson.a.phase.3.randomized.open-label.multicenter.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DA+phase+3+randomized%2C+open-label%2C+multicenter+study+of+isatuximab%2C+pomalidomide%2C+and+low-dose+dexamethasone+vs+pomalidomide+and+low-dose+dexamethasone+in+relapsed % 2Frefractory+multiple+myeloma" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S873</td> <td style="padding: 5px; text-align: center;">Pawlyn C</td> <td style="padding: 5px;">Efficacy of quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) induction for newly diagnosed myeloma patients: Analsis of the myeloma XI study by molecular risk</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267456/charlotte.pawlyn.efficacy.of.quadruplet.kcrd.28carfilzomib.cyclophosphamide.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Ds873" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S874</td> <td style="padding: 5px; text-align: center;">Avet-Loiseau H</td> <td style="padding: 5px;">Efficacy of daratumumab + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma based on minimal residual disease status: Analysis of CASSIOPEIA</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267457/herv.avet-loiseau.efficacy.of.daratumumab.2B.bortezomib.thalidomide.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DEfficacy+of+daratumumab+%2B+bortezomib%2Fthalidomide%2Fdexamethasone+%28D-VTd%29+in+transplant-eligible+newly+diagnosed+multiple+myeloma+based+on+minimal+residual+disease+status % 3A+Analysis+of+CASSIOPEIA" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF586</td> <td style="padding: 5px; text-align: center;">Larocca A</td> <td style="padding: 5px;">Sparing steroids in elderly intermediate-fit newly diagnosed multiple myeloma patients treated with a dose/schedule-adjusted Rd-R vs. continuous Rd: Results of RV-MM-PI-0752 phase III randomized study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266385/alessandra.larocca.sparing.steroids.in.elderly.intermediate-fit.newly.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Delderly+intermediate-fit+newly+diagnosed+multiple+myeloma+patients+treated+with+a+dose%2Fschedule-adjusted+Rd-R+vs.+continuous+Rd % 3A+Results+of+RV-MM-PI-0752+phase+III+randomized+study" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF591</td> <td style="padding: 5px; text-align: center;">Dimopoulos MA</td> <td style="padding: 5px;">Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma: Updated subgroup analysis of POLLUX based on cytogenetic risk</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266390/meletios.a.dimopoulos.efficacy.and.safety.of.daratumumab.lenalidomide.and.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Defficacy%2Bsafety%2Bdexamethasone+%28d-rd%29%2Brelapsed+or+refractory+multiple+myeloma%3A+updated+subgroup+analysis%2Bpollux+based % 2Bcytogenetic+risk" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF592</td> <td style="padding: 5px; text-align: center;">Hulin C</td> <td style="padding: 5px;">Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma MAIA</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266391/cyrille.hulin.impact.of.age.on.efficacy.and.safety.of.daratumumab.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dimpact%2Bage%2Befficacy%2Bsafety%2Bdaratumumab%2Bcombination%2Blenalidomide%2Bdexamethasone+%28d-rd%29%2Bpatients % 2Btransplant-ineligible+newly+diagnosed+multiple+myeloma+maia" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF595</td> <td style="padding: 5px; text-align: center;">Dimopoulos MA</td> <td style="padding: 5px;">Pomalidomide + bortezomib + low-dose dexamethasone after one prior line of therapy in patients with lenalidomide-pretreated multiple myeloma: Subgroup analysis of the phase 3 OPTIMISMM trial</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266394/meletios.a.dimopoulos.pomalidomide.2B.bortezomib.2B.low-dose.dexamethasone.after.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dmultiple+myeloma" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF596</td> <td style="padding: 5px; text-align: center;">Weisel K</td> <td style="padding: 5px;">Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma: Updated subgroup analysis of CASTOR based on cytogenetic risk</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266395/katja.c.weisel.efficacy.and.safety.of.daratumumab.bortezomib.and.dexamethasone.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Defficacy%2Bsafety%2Bdexamethasone+%28d-vd%29%2Brelapsed+or+refractory+multiple+myeloma%3A+updated+subgroup+analysis%2Bcastor+based % 2Bcytogenetic+risk" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF597</td> <td style="padding: 5px; text-align: center;">Mai EK</td> <td style="padding: 5px;">High dose melphalan (200mg/m2) and autologous transplantation in newly-diagnosed multiple myeloma up to the age of 70 yeas: A subgroup analysis from the phase III GMMG-MM5 trial</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266396/elias.k.mai.high.dose.melphalan.28200mg.m229.and.autologous.transplantation.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dpf597" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF598</td> <td style="padding: 5px; text-align: center;">Hulin C</td> <td style="padding: 5px;">Stem cell yield and transplantation in transplant-eligible newly diagnosed newly diagnosed multiple myeloma patientes receiving daratumumab + bortezomib/thalidomide/dexamethasone (D-VTd): Phase III CASSIOPEIA study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266397/cyrille.hulin.stem.cell.yield.and.transplantation.in.transplant-eligible.newly.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dmultiple+myeloma" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF603</td> <td style="padding: 5px; text-align: center;">Perrot A</td> <td style="padding: 5px;">Faster &amp; sustained improvement in heath-related quality of life in transplant-ineligible newly diagnosed multiple myeloma pts treated with daratumumab, lenalidomide &amp; dexamethasone (D-Rd) vs. Rd: MAIA</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266402/aurore.perrot.faster.26.sustained.improvement.in.health-related.quality.of.life.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dpf603" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF617</td> <td style="padding: 5px; text-align: center;">Facon T</td> <td style="padding: 5px;">Impact of early vs late relapse in transplant-ineligible newly diagnosed multiple myeloma: A sub analysis of the phase 3 FIRST trial</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266416/thierry.facon.impact.of.early.vs.late.relapse.in.transplant-ineligible.newly.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dpf617" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF626</td> <td style="padding: 5px; text-align: center;">Schjesvold F</td> <td style="padding: 5px;">Health-related quality of life outcomes of oral ixazomib maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma from TOURMALINE-MM3</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266425/fredrik.schjesvold.health-related.quality.of.life.28hrqol29.outcomes.of.oral.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dhealth-related+quality%2Blife+outcomes%2Boral+ixazomib+maintenance+therapy+post+autologous+stem+cell+transplant+%28asct%29%2Bnewly+diagnosed+multiple+myeloma % 2Btourmaline-mm3" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF646</td> <td style="padding: 5px; text-align: center;">He J</td> <td style="padding: 5px;">Association between bortezomib cumulative dose and treatment-free interval in transplant-ineligible patients with previously untreated multiple myeloma</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266445/jianming.he.association.between.bortezomib.cumulative.dose.and.treatment-free.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3DAssociation+between+bortezomib+cumulative+dose+and+treatment-free+interval+in+transplant-ineligible+patients+with+previously+untreated+multiple+myeloma" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS1377</td> <td style="padding: 5px; text-align: center;">Roussel M</td> <td style="padding: 5px;">Improvement in health-related qualityof life for newly diagnosed multiple myeloma transplant-eligible patients treated with daratumumab, bortezomib, thalidomide, and dexamethasone: CASSIOPEIA study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266994/murielle.roussel.improvement.in.health-related.quality.of.life.for.newly.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dps1377" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS1379</td> <td style="padding: 5px; text-align: center;">Mateos MV</td> <td style="padding: 5px;">Safety and efficacy of once-weekly carfilzomib dosing in frail patients: A subgroup analysis from the phase 3 A.R.R.O.W. study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266996/mara-victoria.mateos.safety.and.efficacy.of.once-weekly.carfilzomib.dosing.in.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D2%2Amedia % 3D3" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS1382</td> <td style="padding: 5px; text-align: center;">Goldschmidt H</td> <td style="padding: 5px;">Depening responses seen with ixazomib maintenance post-autologous stem cell transplantation are association with prolonged progression-free survival - Analysis from the TOURMALINE-MM3 study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266999/hartmut.goldschmidt.deepening.responses.seen.with.ixazomib.maintenance.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Dps1382" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS1387</td> <td style="padding: 5px; text-align: center;">Facon T</td> <td style="padding: 5px;">Carfilzomib in relapsed and refractory multiple myeloma: Frailty subgroup analysis from phase 3 ASPIRE and ENDEAVOR</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267004/thierry.facon.carfilzomib.in.relapsed.and.refractory.multiple.myeloma.28rrmm29.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dcarfilzomib%2Brelapsed%2Brefractory+multiple+myeloma%3A+frailty+subgroup+analysis%2Bphase+3+aspire % 2Bendeavor" target="_blank">weiterlesen</a></td> </tr> <tr> <td class="xl66" style="padding: 5px;" colspan="4" height="20"> <h4>Hodgkin Lymphom</h4> </td> </tr> <tr> <td style="text-align: center;" height="20">S819</td> <td style="padding: 5px; text-align: center;">Fuchs M</td> <td style="padding: 5px;">PET after 2 cycles of ABVD in patients with early-stage favorable Hodgkin lymphoma treated within the phase 3 GHSG HD16 study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267402/michael.fuchs.pet.after.2.cycles.of.abvd.in.patients.with.early-stage.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3DPET+after+2+cycles+of+ABVD+in+patients+with+early-stage+favorable+Hodgkin+lymphoma+treated+within+the+phase+3+GHSG+HD16+study" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S820</td> <td style="padding: 5px; text-align: center;">Gallamini A</td> <td style="padding: 5px;">Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267403/andrea.gallamini.frontline.brentuximab.vedotin.with.chemotherapy.for.stage.3.4.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DFrontline+brentuximab+vedotin+with+chemotherapy+for+stage+3%2F4+classical+Hodgkin+lymphoma % 3A+3-year+update+of+the+ECHELON-1+study" target="_blank">weiterlesen</a></td> </tr> <tr> <td class="xl66" style="padding: 5px;" colspan="4" height="20"> <h4>Thalass&auml;mie</h4> </td> </tr> <tr> <td style="text-align: center;" height="20">S140</td> <td style="padding: 5px; text-align: center;">Kulozik AE</td> <td style="padding: 5px;">Results from the phase 3 NORTHSTAR-3 study evaluating lentiglobin gene therapy in patients with transfusion-dependent beta-thalassaemia and a beta0 or IVS-I-110 mutation at both alleles of the HBB gene</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267341/andreas.e.kulozik.results.from.the.phase.3.northstar-3.study.evaluating.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Ds140" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S141</td> <td style="padding: 5px; text-align: center;">Walters MC</td> <td style="padding: 5px;">Clinical outcomes of lentiglobin gene therapy for transfusion-dependent beta-thalassaemia (TDT) following completion of the NORTHSTAR (HGB-204) study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267342/mark.c.walters.clinical.outcomes.of.lentiglobin.gene.therapy.for.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Ds141" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S144</td> <td style="padding: 5px; text-align: center;">Kattamis A</td> <td style="padding: 5px;">A multicentre, randomized, non-inferiority trial comparing the efficac of deferiprone versus deferasirox in pediatric patients affected by transfusion-dependent hemoglobinopathies (DEEP-2 trial)</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267345/antonis.kattamis.a.multicentre.randomized.non-inferiority.trial.comparing.the.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Ds144" target="_blank">weiterlesen</a></td> </tr> <tr> <td class="xl66" style="padding: 5px;" colspan="4" height="20"> <h4>Sonstige</h4> </td> </tr> <tr> <td style="text-align: center;" height="20">S863</td> <td style="padding: 5px; text-align: center;">Schrezenmeier H</td> <td style="padding: 5px;">One-year efficacy of ravulizumab (ALXN1210) in adult patients with paroxysmal nocturnal hemaglobinuria naive to complement inhibitors</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267446/hubert.schrezenmeier.one-year.efficacy.of.ravulizumab.28alxn121029.in.adult.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3Ds863" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S875</td> <td style="padding: 5px; text-align: center;">Comenzo RL</td> <td style="padding: 5px;">Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (CYBORD) in patients with newly diagnosed amyloid light chain amyloidosis: Updated safety run in relults of ANDROMEDA</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2018/stockholm/215618/giampaolo.merlini.subcutaneous.daratumumab.28dara.sc29.2B.cyclophosphamide.html?f=topic=1574*media=3" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PF614</td> <td style="padding: 5px; text-align: center;">Tedeschi A</td> <td style="padding: 5px;">Patient-reported outcomes from the INNOVATE study: Results of ibrutinib-rituximab in Waldenstr&ouml;m macroglobulinemia&nbsp;</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266413/alessandra.tedeschi.patient-reported.outcomes.from.the.innovate.study.results.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dpatient-reported+outcomes%2Binnovate+study%3A+results%2Bibrutinib-rituximab%2Bwaldenstr%C3 % B6m+macroglobulinemia" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">S147</td> <td style="padding: 5px; text-align: center;">Vichinsky E</td> <td style="padding: 5px;">Results from the randomized placebo-controlled phase 3 hope trial of voxelotor in adults and adolescents with sickle cell disease</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/267348/j.howard.results.from.the.randomized.placebo-controlled.phase.3.hope.trial.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch % 3DResults+from+the+randomized+placebo-controlled+phase+3+hope+trial+of+voxelotor+in+adults+and+adolescents+with+sickle+cell+disease" target="_blank">weiterlesen</a></td> </tr> <tr> <td style="text-align: center;" height="20">PS1260</td> <td style="padding: 5px; text-align: center;">Zinzani PL</td> <td style="padding: 5px;">Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides: Results from the MAVORIC study</td> <td class="xl67" style="text-align: center;"><a href="https://library.ehaweb.org/eha/2019/24th/266877/pier.luigi.zinzani.efficacy.of.mogamulizumab.in.previously.treated.patients.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DEfficacy+of+mogamulizumab+in+previously+treated+patients+with+less+advanced+mycosis+fungoides % 3A+Results+from+the+MAVORIC+study" target="_blank">weiterlesen</a></td> </tr> </tbody> </table></p>